Overview
- Skillfully reviews cutting-edge advances in stem cell biology as applied to regnerative medicine and ocular disease
- Provides expert viewpoints on key hurdles and challenges to successful implementation of stem cell-derived therapies in the clinical domain
- Offers a multi-disciplinary, broad understanding of cell-based therapies for ocular diseases by incorporating perspectives from biomedical scientists, physicians, and engineers
- Examines the connection between cell therapy and gene editing, in particular in relation to ocular disease
Part of the book series: Fundamental Biomedical Technologies (FBMT)
Access this book
Tax calculation will be finalised at checkout
Other ways to access
Table of contents (8 chapters)
-
Front Matter
-
Back Matter
Keywords
About this book
This book also
- Skillfully reviews cutting-edge advances in stem cell biology as applied to regenerative medicine and ocular disease
- Provides expert viewpoints on key hurdles and challenges to successful implementation of stem cell-derived therapies in the clinical domain
- Offers a multi-disciplinary, broad understanding of cell-based therapies for ocular diseases by incorporating perspectives from biomedical scientists, physicians, and engineers
- Examines the connection between cell therapy and gene editing, in particular relation to ocular disease
Editors and Affiliations
About the editors
Brian Ballios, M.D., Ph.D., Senior Research Associate and Resident Physician in the Department of Ophthalmology and Vision Sciences, University of Toronto, received his B.Sc.Eng. in Engineering Chemistry from Queen’s University in 2007. He then completed a combined MD/PhD Program at the University of Toronto in 2015. During his graduate work, he developed new approaches to the transplantation of stem cells and their progeny for the treatment of retinal degeneration. His interests lie at the intersection of retinal neurobiology and applied science, as related to stem cell biology and bioengineering. He developed the first injectable biomaterial-based delivery system for stem cell transplantation in the retina. In 2016, he joined the Department of Ophthalmology and Vision Sciences as a Senior Research Associate, while also completing an ophthalmology residency.
Michael Young, Ph.D., Associate Scientist at the Schepens Eye Research Institute, received his BS degree in behavioral neuroscience from the University of Pittsburgh in 1989. He then received his PhD in anatomy/neuroscience from the University of Cambridge in 1995. A postdoctoral fellowship at the Institute of Ophthalmology, University College, London in 1995 was followed by a two-year postdoctoral fellowship at the Massachusetts Institute of Technology, Department of Brain and Cognitive Sciences. In 1998, Young joined the Schepens Eye Research Institute as an Investigator. He was elected the Director of the Minda deGunzburg Center for Ocular Regeneration. In 2008, he was promoted to Associate Professor in the Department of Ophthalmology, Harvard Medical School. He is now also Co-director of the Ocular Regenerative Medicine Institute at MEE/HMS.
Bibliographic Information
Book Title: Regenerative Medicine and Stem Cell Therapy for the Eye
Editors: Brian G. Ballios, Michael J. Young
Series Title: Fundamental Biomedical Technologies
DOI: https://doi.org/10.1007/978-3-319-98080-5
Publisher: Springer Cham
eBook Packages: Biomedical and Life Sciences, Biomedical and Life Sciences (R0)
Copyright Information: Springer Nature Switzerland AG 2018
Hardcover ISBN: 978-3-319-98079-9Published: 04 March 2019
eBook ISBN: 978-3-319-98080-5Published: 18 February 2019
Series ISSN: 1559-7083
Series E-ISSN: 2626-8655
Edition Number: 1
Number of Pages: X, 212
Number of Illustrations: 2 b/w illustrations, 19 illustrations in colour
Topics: Regenerative Medicine/Tissue Engineering, Stem Cells, Ophthalmology, Biomedical Engineering/Biotechnology